Effect of Rifampicin and Isoniazid on Liver of Albino Rat: A Review
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Tuberculosis is infectious disease treated by the first line antituberculosis medications, rifampicin and isoniazid. Despite their high efficacy, prolonged use of these drugs either individually or in combination is frequently associated with hepatotoxicity, which represents a major limitation in tuberculosis treatment. One of the vital organs in the human body is liver, that controls various metabolic and biochemical methods, such as breakdown of lipid, proteins, carbohydrates and amino acids. Isoniazid, an effective mycobactericidal drug and rifampicin, a semisynthetic rifamycin antibacterial, are known for causing liver injury by producing reactive metabolites damaging hepatocellular integrity. Rifampicin and isoniazid produce major biochemical, histology and molecular changes in the liver, as revealed the reviewed studies consistently. These include decreased glutathione, superoxide dismutase and catalase whereas increased blood liver enzymes, bilirubin, lipid peroxidation, and inflammatory cytokines. Histopathological studies revealed hepatocellular necrosis, steatosis, cholestasis, inflammation, portal triaditis and in cases of prolonged exposure, fibrosis are frequently seen. Previous literature showed hepatotoxicity mediated by oxidative stress, endoplasmic reticulum stress, cytochrome P450 enzyme (CYP2E1) activation, lipid metabolism dysregulation, bile acid transport imbalance, mitochondrial malfunction and immune inflammatory reactions. Rifampicin is shown to enhance isoniazid induced hepatotoxicity via increasing bioactivation pathways, whereas combination therapy often induces severe liver damage than either medication alone. There is strong evidence that the hepatotoxicity resulting from isoniazid and rifampicin is complex and dose and duration dependent. Antitubercular therapy all need an understanding of TB therapy creating successful hepatoprotective precautions.
Fields of Study & Subjects
Drug-Induced Hepatotoxicity and Protection
Liver physiology and pathology
Tuberculosis Research and Epidemiology
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 26 March 2026
- Language
- EN